Analysts expect Cirrus Logic, Inc. (NASDAQ:CRUS) to report $0.46 EPS on May, 2.They anticipate $0.27 EPS change or 36.99% from last quarter’s $0.73 EPS. CRUS’s profit would be $29.15M giving it 21.22 P/E if the $0.46 EPS is correct. After having $1.40 EPS previously, Cirrus Logic, Inc.’s analysts see -67.14% EPS growth. The stock increased 0.80% or $0.31 during the last trading session, reaching $39.04. About 166,904 shares traded. Cirrus Logic, Inc. (NASDAQ:CRUS) has declined 32.88% since April 4, 2017 and is downtrending. It has underperformed by 44.43% the S&P500.
Sands Capital Management Llc decreased Biomarin Pharmaceutical Inc (BMRN) stake by 4.12% reported in 2017Q4 SEC filing. Sands Capital Management Llc sold 331,781 shares as Biomarin Pharmaceutical Inc (BMRN)’s stock declined 13.73%. The Sands Capital Management Llc holds 7.73 million shares with $689.00 million value, down from 8.06 million last quarter. Biomarin Pharmaceutical Inc now has $13.62B valuation. The stock decreased 0.12% or $0.1 during the last trading session, reaching $77.32. About 87,279 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 11.55% since April 4, 2017 and is downtrending. It has underperformed by 23.10% the S&P500.
Since December 14, 2017, it had 0 buys, and 14 sales for $10.22 million activity. The insider LAWLIS V BRYAN sold $333,150. $1.25 million worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares were sold by BIENAIME JEAN JACQUES. Ajer Jeffrey Robert sold $366,475 worth of stock or 4,368 shares. $320,254 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was sold by Davis George Eric. Shares for $1.34M were sold by FUCHS HENRY J. HERON ELAINE J also sold $71,116 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Thursday, December 14.
Investors sentiment increased to 1.21 in 2017 Q4. Its up 0.08, from 1.13 in 2017Q3. It improved, as 37 investors sold BMRN shares while 112 reduced holdings. 51 funds opened positions while 130 raised stakes. 172.01 million shares or 0.29% more from 171.51 million shares in 2017Q3 were reported. 3 were reported by Clarivest Asset Limited Com. 10,018 are owned by Westpac Bk. Minnesota-based Kopp Inv Advsrs Llc has invested 0.89% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Rhenman Prtnrs Asset Management owns 139,849 shares or 1.68% of their US portfolio. Alliancebernstein LP owns 148,380 shares. Great West Life Assurance Com Can reported 0.02% stake. Ameritas Prtn Inc reported 3,126 shares or 0.01% of all its holdings. Eventide Asset Mngmt Limited Liability Corp holds 0.35% or 75,000 shares. Hudson Bay Mngmt Lp invested 0.21% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Synovus Fin Corp accumulated 28,433 shares. The North Carolina-based Ironsides Asset Advisors Limited Liability Company has invested 0.13% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Proshare Advsr Limited Liability has invested 0.11% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Ing Groep Nv accumulated 0.01% or 4,722 shares. Nuveen Asset Management Ltd Liability Co holds 3,970 shares. Jgp Global Gestao De Recursos Ltda accumulated 16,977 shares or 0.74% of the stock.
Sands Capital Management Llc increased Transdigm Group Inc (NYSE:TDG) stake by 33,000 shares to 40,554 valued at $11.14 million in 2017Q4. It also upped Dollar Gen Corp (NYSE:DG) stake by 51,654 shares and now owns 70,476 shares. Makemytrip Limited Mauritius (NASDAQ:MMYT) was raised too.
Among 27 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. BioMarin Pharmaceutical had 86 analyst reports since August 5, 2015 according to SRatingsIntel. PiperJaffray downgraded the shares of BMRN in report on Monday, November 7 to “Neutral” rating. The rating was maintained by Cowen & Co with “Buy” on Tuesday, July 11. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Buy” rating by Leerink Swann on Tuesday, July 18. Leerink Swann maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Friday, February 23. Leerink Swann has “Outperform” rating and $132 target. The firm earned “Buy” rating on Thursday, July 13 by Deutsche Bank. Barclays Capital downgraded the shares of BMRN in report on Tuesday, November 29 to “Equal-Weight” rating. The company was initiated on Tuesday, February 7 by Morgan Stanley. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Conviction Buy” rating given on Monday, March 7 by Goldman Sachs. The firm earned “Buy” rating on Tuesday, February 16 by Stifel Nicolaus. Leerink Swann maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Tuesday, February 23 with “Outperform” rating.
Analysts await BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report earnings on May, 3. They expect $-0.20 EPS, down 766.67% or $0.23 from last year’s $0.03 per share. After $-0.30 actual EPS reported by BioMarin Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts -33.33% EPS growth.
Cirrus Logic, Inc., a fabless semiconductor company, develops, makes, and markets analog and mixed-signal integrated circuits for a range of consumer and industrial markets. The company has market cap of $2.47 billion. The firm offers portable and non-portable audio, and other products. It has a 14.08 P/E ratio. The Company’s products include analog and mixed-signal audio converters, and digital signal processing products for mobile applications; codecs-chips that integrate analog-to-digital converters and digital-to-analog converters into a single IC; smart codecs, a codec with digital signal processer; amplifiers; micro-electromechanical systems microphones; digital interface products; and standalone digital signal processors.
Among 15 analysts covering Cirrus Logic (NASDAQ:CRUS), 9 have Buy rating, 2 Sell and 4 Hold. Therefore 60% are positive. Cirrus Logic had 47 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, October 28 by Canaccord Genuity. The stock has “Buy” rating by Rosenblatt on Thursday, July 23. The firm has “Buy” rating given on Monday, November 30 by Dougherty & Company. The firm earned “Underperform” rating on Tuesday, February 6 by Bank of America. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, August 2 report. The rating was initiated by Bank of America on Monday, September 18 with “Sell”. The rating was upgraded by Stifel Nicolaus on Thursday, July 23 to “Buy”. On Thursday, October 13 the stock rating was maintained by Stifel Nicolaus with “Buy”. The stock of Cirrus Logic, Inc. (NASDAQ:CRUS) earned “Hold” rating by Craig Hallum on Thursday, February 2. The company was downgraded on Wednesday, March 1 by Oppenheimer.
Investors sentiment decreased to 0.89 in Q4 2017. Its down 0.13, from 1.02 in 2017Q3. It worsened, as 42 investors sold Cirrus Logic, Inc. shares while 108 reduced holdings. 45 funds opened positions while 88 raised stakes. 55.95 million shares or 0.50% more from 55.67 million shares in 2017Q3 were reported. Us Bank & Trust De invested in 0% or 3,914 shares. Eqis Capital Management invested in 10,480 shares. 30,512 were accumulated by Jane Street Gp Lc. Prudential Fincl reported 0.07% in Cirrus Logic, Inc. (NASDAQ:CRUS). Retirement Of Alabama holds 0.02% or 82,323 shares. Sprott Inc has invested 2.07% of its portfolio in Cirrus Logic, Inc. (NASDAQ:CRUS). New Mexico Educational Retirement Board owns 15,800 shares or 0.03% of their US portfolio. The Missouri-based Amer Century Cos has invested 0.01% in Cirrus Logic, Inc. (NASDAQ:CRUS). Benjamin F Edwards And Inc reported 300 shares stake. Origin Asset Management Limited Liability Partnership invested in 0.62% or 208,147 shares. Tiaa Cref Investment Mgmt Limited Liability Corporation invested in 0.01% or 374,135 shares. 58,659 are owned by Holderness. Panagora Asset Mgmt invested in 0% or 10,259 shares. Emerald Advisers Incorporated Pa has invested 0.22% in Cirrus Logic, Inc. (NASDAQ:CRUS). Oregon Pub Employees Retirement Fund holds 0.02% or 23,746 shares in its portfolio.